Dutch scientist M.A. Yacobi has discovered a medical treatment that can prevent premature death for people suffering from Hypertension (high blood pressure), Atherosclerosis (hardening of the arteries) and elevated cholesterol levels.
These three medical conditions are caused by the build-up of bodily waste, leading to hardening of the arteries and ultimately resulting in organ failure, which is the major cause of coronary and vascular disease. Worldwide, millions of people suffer from this condition, often with fatal outcome.
Groundbreaking discovery regulates metabolism This newly developed medication successfully ensures that bodily waste products ultimately leave the body. The unsettled metabolism will start functioning and blood circulation and organs will again be regulated. This significant discovery allows the body to regain its normal function and the patient to remain healthy.
The photo material that can be found at http://www.soulberc.com/causestreatment.html shows which waste products are removed.
'Impact on society' 'This is a revolutionary treatment in this medical field and it will have a major impact on society. So many people suffer from Hypertension, elevated Cholesterol and Atherosclerosis. This is good news for those people', says Ahmed Soulaimani, managing director at Soulberc Consultants, the company supporting the scientist. 'These are the main causes of coronary and vascular disease and now they can be eradicated drastically. We suspect that more metabolic diseases such as diabetes and migraine will also benefit from this research.' Out-of-the box The treatment was discovered by the skilled medical researcher M.A.
Yacobi from Enschede. An innovative and 'out of the box' thinker in the medical field, he has conducted independent medical research for over thirty years now. His medical innovations have far-reaching consequences for the patients that benefit from his life-changing treatments.
Soulberc Consultants The Company Soulberc Consultants provides independent medical advice and specialises in the commercialization of biomedical innovations and inventions. Soulberc Consultants is presently attracting parties from all over the world for this new innovation. As a result, it is expected that within months patients worldwide will be able to be treated with this therapy.
Photo material can be downloaded by the press free of copyright via http://www.soulberc.nl/Persmedia.html.
SOURCE Soulberc Consultants -0- 03/29/2012 /CONTACT: Note for the editors/Not for publication: For more information please contact Soulberc Consultants, partners in biomedical innovations. Spokesperson: Ahmed Soulaimani, t. +31-6-18053948 e. email@example.com en http://www.soulberc.nl.
CO: Soulberc Consultants ST: United States of America United Kingdom Netherlands IN: BIO HEA MTC MEQ PHA SU: PDT TRI PRN -- UKW812 -- 0000 03/29/2012 13:30:00 EDT http://www.prnewswire.c